» Articles » PMID: 28283585

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail

Overview
Journal Oncologist
Specialty Oncology
Date 2017 Mar 12
PMID 28283585
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence and cost burden of HMA failure are unknown yet needed to appreciate the magnitude and significance of such failure.

Methods: We analyzed a de-identified dataset of over 5 million individuals with private health insurance in the U.S. to estimate MDS incidence, prevalence, and treatments. Based on MDS provider interviews, a conceptual model of MDS patient management was constructed to create a new, claims-relevant and drug development-relevant definition of HMA treatment failure. This algorithm was used to define resource encumbrance of MDS patients in whom HMA treatment failed.

Results: We estimated an MDS incidence rate of ∼70 cases per 100,000 enrollees per year and a prevalence of 155 cases per 100,000 enrollees. The proportion of MDS patients receiving HMA treatment was low (∼3%), and treatment was typically initiated within 1 year of the first MDS claim. Notably, HMA-treated individuals were older and had more comorbidities than the overall MDS cohort. Total health care costs of managing MDS patients after HMA failure were high (∼$77,000 during the first 6 months) and were driven primarily by non-pharmacy costs.

Conclusion: This study quantifies for the first time the burden of significant unmet need in caring for MDS patients following HMA treatment failure. 2017;22:379-385 U.S.-based treatment patterns among MDS patients demonstrate the significant clinical, financial, and health care burden associated with HMA failure and call for active therapies for this patient population.

Citing Articles

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients.

Morlock R, Fong C, Castaldi F, Paine T, Collett D, Enjeti A EJHaem. 2024; 5(3):535-540.

PMID: 38895084 PMC: 11182385. DOI: 10.1002/jha2.930.


Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.

Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan A J Oncol Pharm Pract. 2024; 30(4):721-736.

PMID: 38509812 PMC: 11118786. DOI: 10.1177/10781552241238979.


An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.

Stahl M, Abdel-Wahab O, Wei A, Savona M, Xu M, Xie Z Blood Adv. 2022; 7(12):2709-2714.

PMID: 36260702 PMC: 10333740. DOI: 10.1182/bloodadvances.2022008747.


Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.

Warlick E, Ustun C, Andreescu A, Bonagura A, Brunner A, Chandra A Cancer. 2021; 127(23):4339-4347.

PMID: 34375439 PMC: 8578257. DOI: 10.1002/cncr.33826.


161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P Blood Adv. 2018; 2(12):1459-1469.

PMID: 29941459 PMC: 6020813. DOI: 10.1182/bloodadvances.2017012369.

References
1.
Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. DOI: 10.1182/blood-2005-10-4149. View

2.
Bowling A . Honour your father and mother: ageism in medicine. Br J Gen Pract. 2007; 57(538):347-8. PMC: 2047005. View

3.
Font P, Loscertales J, Soto C, Ricard P, Novas C, Martin-Clavero E . Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol. 2014; 94(4):565-73. DOI: 10.1007/s00277-014-2252-4. View

4.
Cogle C, Ortendahl J, Bentley T, Anene A, Megaffin S, McKearn T . Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Rev Pharmacoecon Outcomes Res. 2015; 16(2):275-84. DOI: 10.1586/14737167.2016.1096200. View

5.
Zeidan A, Kharfan-Dabaja M, Komrokji R . Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2013; 21(2):123-30. PMC: 4124617. DOI: 10.1097/MOH.0000000000000016. View